SI4010082T1 - Multispecifična protitelesa anti-TCR delta variable 1 - Google Patents

Multispecifična protitelesa anti-TCR delta variable 1

Info

Publication number: SI4010082T1
Authority: SI; Slovenia
Prior art keywords: antibodies; tcr delta; multispecific anti; delta variable; variable
Prior art date: 2020-08-14

Application number

SI202130032T

Other languages

English (en)

Inventor

Mark Uden

Mihriban Tuna

Natalie Mount

Robert Good

Joshua Freedman

Shefali Bhumbra

Oliver Nussbaumer

Raj Jaysukhlal Mehta

Original Assignee

GammaDelta Therapeutics Limited,

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-08-14

Filing date

2021-08-14

Publication date

2023-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI4010082(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-08-14 Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en

2021-02-17 Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en

2021-02-17 Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en

2021-08-14 Application filed by GammaDelta Therapeutics Limited, filed Critical GammaDelta Therapeutics Limited,

2023-04-28 Publication of SI4010082T1 publication Critical patent/SI4010082T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Oncology (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)

SI202130032T 2020-08-14 2021-08-14 Multispecifična protitelesa anti-TCR delta variable 1 SI4010082T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
PCT/GB2020/051959 WO2021032963A1 (en)	2019-08-16	2020-08-14	Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en)	2021-02-17	2021-02-17	Anti-TRC delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en)	2021-02-17	2021-02-17	Multispecific anti-TCR delta variable 1 antibodies
EP21756070.5A EP4010082B1 (en)	2020-08-14	2021-08-14	Multispecific anti-tcr delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en)	2020-08-14	2021-08-14	Multispecific anti-tcr delta variable 1 antibodies

Publications (1)

Publication Number	Publication Date
SI4010082T1 true SI4010082T1 (sl)	2023-04-28

Family

ID=80247426

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI202130032T SI4010082T1 (sl)	2020-08-14	2021-08-14	Multispecifična protitelesa anti-TCR delta variable 1
SI202130192T SI4269444T1 (sl)	2020-08-14	2021-08-14	Multispecifična protetelesa anti-tcr delta variable 1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI202130192T SI4269444T1 (sl)	2020-08-14	2021-08-14	Multispecifična protetelesa anti-tcr delta variable 1

Country Status (18)

Country	Link
EP (7)	EP4010082B1 (sl)
JP (1)	JP2023537534A (sl)
KR (1)	KR20230083267A (sl)
CN (1)	CN116209456A (sl)
AU (1)	AU2021323512A1 (sl)
BR (1)	BR112023002741A2 (sl)
CA (1)	CA3188682A1 (sl)
CO (1)	CO2023003009A2 (sl)
DK (2)	DK4269444T5 (sl)
ES (2)	ES2943063T3 (sl)
FI (2)	FI4269444T3 (sl)
IL (1)	IL300517A (sl)
LT (2)	LT4269444T (sl)
MX (1)	MX2023001728A (sl)
PL (2)	PL4269444T3 (sl)
PT (2)	PT4269444T (sl)
SI (2)	SI4010082T1 (sl)
WO (1)	WO2022034562A1 (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4010082B1 (en)	2020-08-14	2023-01-25	GammaDelta Therapeutics Limited	Multispecific anti-tcr delta variable 1 antibodies
EP4544302A1 (en) *	2022-06-23	2025-04-30	LAVA Therapeutics N.V.	Assay for t cell dependent multispecific compounds
WO2024193459A1 (en) *	2023-03-17	2024-09-26	Nanjing Legend Biotech Co., Ltd.	METHODS OF CULTURING Vδ1 T CELLS

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2546268A1 (en)	2011-07-13	2013-01-16	F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H.	Internalising immunoglobulin
WO2015063069A1 (en) *	2013-10-28	2015-05-07	Benjamin Felder	Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) *	2015-04-15	2015-05-27	Tc Biopharm Ltd	Gamma delta T cells and uses thereof
CN108350428B (zh)	2015-06-09	2022-04-22	淋巴-淋巴细胞活化技术公司	用于生产TCRγδ+T细胞的方法
ES2925261T3 (es)	2015-10-30	2022-10-14	Cancer Research Tech Ltd	Expansión de células T gamma delta residentes en tejidos no hematopoyéticos y usos de estas células
MX2018013864A (es)	2016-05-12	2019-06-10	Adicet Bio Inc	Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.
GB201612520D0 (en)	2016-07-19	2016-08-31	F-Star Beta Ltd	Binding molecules
US20180028566A1 (en)	2016-07-29	2018-02-01	New York University	Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en)	2017-05-15	2020-01-28	Google Llc	Near-eye display with extended effective eyebox via eye tracking
CN111148761B (zh)	2017-06-25	2024-02-13	西雅图免疫公司	多特异性抗体及其制备和使用方法
EP3743081A4 (en)	2018-01-23	2021-12-01	New York University	SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
WO2020060406A1 (en) *	2018-09-19	2020-03-26	Lava Therapeutics B.V.	Novel bispecific antibodies for use in the treatment of hematological malignancies
GB201818243D0 (en)	2018-11-08	2018-12-26	Gammadelta Therapeutics Ltd	Methods for isolating and expanding cells
WO2020159368A1 (en) *	2019-02-01	2020-08-06	Lava Therapeutics B.V.	Novel cd40-binding antibodies
CN114341176A (zh)	2019-04-08	2022-04-12	纪念斯隆凯特琳癌症中心	Cd19抗体及其使用方法
US20220290101A1 (en)	2019-08-16	2022-09-15	GammaDelta Therapeutics Limited	Ex vivo gamma delta t cell populations
BR112022002837A2 (pt)	2019-08-16	2022-05-10	Gammadelta Therapeutics Ltd	Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo
EP4010082B1 (en)	2020-08-14	2023-01-25	GammaDelta Therapeutics Limited	Multispecific anti-tcr delta variable 1 antibodies
IL305024A (en)	2021-02-17	2023-10-01	Gammadelta Therapeutics Ltd	Antibodies against variable TCR delta 1

2021
- 2021-08-14 EP EP21756070.5A patent/EP4010082B1/en active Active
- 2021-08-14 SI SI202130032T patent/SI4010082T1/sl unknown
- 2021-08-14 PL PL23187269.8T patent/PL4269444T3/pl unknown
- 2021-08-14 FI FIEP23187269.8T patent/FI4269444T3/fi active
- 2021-08-14 PL PL21756070.5T patent/PL4010082T3/pl unknown
- 2021-08-14 PT PT231872698T patent/PT4269444T/pt unknown
- 2021-08-14 CA CA3188682A patent/CA3188682A1/en active Pending
- 2021-08-14 MX MX2023001728A patent/MX2023001728A/es unknown
- 2021-08-14 ES ES21756070T patent/ES2943063T3/es active Active
- 2021-08-14 IL IL300517A patent/IL300517A/en unknown
- 2021-08-14 EP EP23187271.4A patent/EP4265643B1/en active Active
- 2021-08-14 LT LTEP23187269.8T patent/LT4269444T/lt unknown
- 2021-08-14 DK DK23187269.8T patent/DK4269444T5/da active
- 2021-08-14 DK DK21756070.5T patent/DK4010082T5/da active
- 2021-08-14 WO PCT/IB2021/057509 patent/WO2022034562A1/en active Application Filing
- 2021-08-14 AU AU2021323512A patent/AU2021323512A1/en active Pending
- 2021-08-14 EP EP23187269.8A patent/EP4269444B1/en active Active
- 2021-08-14 CN CN202180069269.3A patent/CN116209456A/zh active Pending
- 2021-08-14 EP EP23187273.0A patent/EP4269446B1/en active Active
- 2021-08-14 BR BR112023002741A patent/BR112023002741A2/pt unknown
- 2021-08-14 FI FIEP21756070.5T patent/FI4010082T3/fi active
- 2021-08-14 EP EP23187272.2A patent/EP4269445B1/en active Active
- 2021-08-14 JP JP2023510439A patent/JP2023537534A/ja active Pending
- 2021-08-14 LT LTEPPCT/IB2021/057509T patent/LT4010082T/lt unknown
- 2021-08-14 SI SI202130192T patent/SI4269444T1/sl unknown
- 2021-08-14 EP EP23153152.6A patent/EP4218932A3/en active Pending
- 2021-08-14 ES ES23187269T patent/ES2993071T3/es active Active
- 2021-08-14 PT PT217560705T patent/PT4010082T/pt unknown
- 2021-08-14 EP EP23187270.6A patent/EP4265642B1/en active Active
- 2021-08-14 KR KR1020237005145A patent/KR20230083267A/ko active Pending
2023
- 2023-03-13 CO CONC2023/0003009A patent/CO2023003009A2/es unknown

Also Published As

Publication number	Publication date
EP4269446A3 (en)	2024-02-14
EP4265643B1 (en)	2024-06-26
EP4010082A1 (en)	2022-06-15
FI4269444T3 (fi)	2024-09-20
LT4269444T (lt)	2024-09-25
WO2022034562A1 (en)	2022-02-17
CA3188682A1 (en)	2022-02-17
LT4010082T (lt)	2023-03-10
PT4269444T (pt)	2024-09-05
DK4269444T3 (en)	2024-08-19
EP4265643A2 (en)	2023-10-25
EP4269444A3 (en)	2024-02-14
EP4269446B1 (en)	2024-06-26
IL300517A (en)	2023-04-01
EP4218932A2 (en)	2023-08-02
EP4269445B1 (en)	2024-06-26
AU2021323512A1 (en)	2023-04-13
EP4010082B1 (en)	2023-01-25
FI4010082T3 (fi)	2023-04-04
EP4265643A3 (en)	2024-02-14
JP2023537534A (ja)	2023-09-01
EP4265642A2 (en)	2023-10-25
EP4265642A3 (en)	2024-02-14
BR112023002741A2 (pt)	2023-10-10
DK4269444T5 (da)	2024-08-26
DK4010082T5 (da)	2024-08-05
PL4010082T3 (pl)	2023-05-29
SI4269444T1 (sl)	2024-10-30
EP4269445A2 (en)	2023-11-01
PL4269444T3 (pl)	2025-01-13
DK4010082T3 (da)	2023-04-03
EP4269444B1 (en)	2024-06-26
CN116209456A (zh)	2023-06-02
ES2943063T3 (es)	2023-06-08
ES2993071T3 (en)	2024-12-20
MX2023001728A (es)	2023-04-20
EP4269446A2 (en)	2023-11-01
EP4265642B1 (en)	2024-06-26
EP4269444A2 (en)	2023-11-01
EP4218932A3 (en)	2023-09-27
CO2023003009A2 (es)	2023-03-17
PT4010082T (pt)	2023-04-26
EP4269445A3 (en)	2024-02-14
KR20230083267A (ko)	2023-06-09

Publication	Publication Date	Title
DK4269444T3 (en)	2024-08-19	Multispecific anti-tcr delta variable 1 antibodies
IL290537A (en)	2022-04-01	Therapeutic uses of anti-tcr variable delta 1 antibodies
LT4214240T (lt)	2024-11-25	Anti-ccr8 antikūnai
GB202105110D0 (en)	2021-05-26	Anti-CD73 antibodies
GB202111905D0 (en)	2021-10-06	Antibodies
IL300142A (en)	2023-03-01	Anti-IL13Ralpha2 antibodies
ZA202308120B (en)	2024-12-18	Multispecific anti-tcr delta variable 1 antibodies
GB202014851D0 (en)	2020-11-04	SARS-COV-2 antibodies
GB202010652D0 (en)	2020-08-26	Anti-tau antibodies
GB202102222D0 (en)	2021-03-31	Multispecific anti-TCR delta variable 1 antibodies
HK40103477A (en)	2024-07-05	Multispecific anti-tcr delta variable 1 antibodies
HK40103226A (en)	2024-06-28	Multispecific anti-tcr delta variable 1 antibodies
HK40102396A (en)	2024-06-07	Multispecific anti-tcr delta variable 1 antibodies
HK40097714A (en)	2024-03-22	Multispecific anti-tcr delta variable 1 antibodies
HK40104958A (en)	2024-08-02	Multispecific anti-tcr delta variable 1 antibodies
HK40109256A (en)	2024-11-29	Multispecific anti-tcr delta variable 1 antibodies
HK40092859A (en)	2023-12-29	Multispecific anti-tcr delta variable 1 antibodies
GB202203226D0 (en)	2022-04-20	Trays
IL307332A (en)	2023-11-01	New multispecific antibodies
GB202111685D0 (en)	2021-09-29	Anti-tcr delta variable 1 antibodies
GB202102224D0 (en)	2021-03-31	Anti-TRC delta variable 1 antibodies
HK40076337A (en)	2023-02-10	Novel anti-tcr delta variable 1 antibodies
HK40104904A (en)	2024-08-02	Anti-tcr delta variable 1 antibodies
HK40105359A (en)	2024-08-09	Anti-tcr delta variable 1 antibodies
HK40072486A (en)	2022-11-25	Therapeutic uses of anti-tcr delta variable 1 antibodies